Overview of subsequent malignant neoplasms observed post–CD19 CAR T-cell therapy
| . | Hematologic malignancy (n = 3) . | Solid tumor (n = 4) . |
|---|---|---|
| Diagnosis | AML (n = 2) MDS (n = 1) | Cholangiocarcinoma Synovial sarcoma Melanoma Thyroid carcinoma |
| Median (range) time from CAR T-cell infusion to diagnosis of SMN, y | 1.2 (0.6-1.6) | 5.9 (3.2-8.2) |
| Median (range) time from initial diagnosis to diagnosis of SMN, y | 3.7 (1.1-4.2) | 9.6 (8.2-12.5) |
| History of alloHSCT before SMN | Yes (n = 2) | Yes (n = 4) |
| Current status | 2 patients remain alive in remission after alloHSCT; 1 died of progressive disease | 3 patients remain alive in remission; 1 died of surgical complications |
| . | Hematologic malignancy (n = 3) . | Solid tumor (n = 4) . |
|---|---|---|
| Diagnosis | AML (n = 2) MDS (n = 1) | Cholangiocarcinoma Synovial sarcoma Melanoma Thyroid carcinoma |
| Median (range) time from CAR T-cell infusion to diagnosis of SMN, y | 1.2 (0.6-1.6) | 5.9 (3.2-8.2) |
| Median (range) time from initial diagnosis to diagnosis of SMN, y | 3.7 (1.1-4.2) | 9.6 (8.2-12.5) |
| History of alloHSCT before SMN | Yes (n = 2) | Yes (n = 4) |
| Current status | 2 patients remain alive in remission after alloHSCT; 1 died of progressive disease | 3 patients remain alive in remission; 1 died of surgical complications |
AML, acute myeloid leukemia; alloHSCT, allogeneic HSCT; MDS, myelodysplastic syndrome.